Cargando…

Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure

BACKGROUND: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Aali, Ehsan, Ghaznavi, Habib, Soltanpour, Mohammad Soleiman, Mahmoudian, Massoud, Shafiei, Massoumeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shiraz University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966930/
https://www.ncbi.nlm.nih.gov/pubmed/33753958
http://dx.doi.org/10.30476/ijms.2019.82057.0
_version_ 1783665767642824704
author Aali, Ehsan
Ghaznavi, Habib
Soltanpour, Mohammad Soleiman
Mahmoudian, Massoud
Shafiei, Massoumeh
author_facet Aali, Ehsan
Ghaznavi, Habib
Soltanpour, Mohammad Soleiman
Mahmoudian, Massoud
Shafiei, Massoumeh
author_sort Aali, Ehsan
collection PubMed
description BACKGROUND: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the pharmacotherapy of heart failure (HF). This study aimed to investigate the possible beneficial action of mebudipine in a rat model of HF. METHODS: The present study carried out in the Department of Pharmacology at the Iran University of Medical Sciences during the years of 2009-2011. An experimental model of HF was induced in male Wistar rats using doxorubicin (DOX). The rats were divided into five groups with seven animals in each group: normal control group, DOX-induced HF control groups, and treatment groups. The animals were administered DOX for 15 days. A consistent deterioration occurred after a four-week rest period. The animals were then treated with intraperitoneal mebudipine (0.5 mg/kg) and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal volume of distilled water for 15 days. The plasma levels of big endothelin-1 (BET-1), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), as well as the clinical status (heart rate and blood pressure), were assessed before and after treatment. Statistical analysis was performed with SPSS software using parametric and nonparametric ANOVA. RESULTS: Mebudipine and amlodipine reversed the increased plasma BET-1 values in the treated animals when compared with the HF control group (0.103 and 0.112 vs 0.231 pg/mL, respectively). The increased plasma levels of AST, ALT, CK-MB, and LDH were also reversed in the HF animals that received mebudipine or amlodipine. CONCLUSION: The administration of mebudipine to HF animals, akin to amlodipine, palliated the clinical and biochemical signs of the disease in the present study. The abstract was presented in the Iranian Congress of Physiology and Pharmacology as a poster and published in the Scientific Information Database as a supplement (2015; Vol 22).
format Online
Article
Text
id pubmed-7966930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shiraz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-79669302021-03-21 Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure Aali, Ehsan Ghaznavi, Habib Soltanpour, Mohammad Soleiman Mahmoudian, Massoud Shafiei, Massoumeh Iran J Med Sci Original Article BACKGROUND: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the pharmacotherapy of heart failure (HF). This study aimed to investigate the possible beneficial action of mebudipine in a rat model of HF. METHODS: The present study carried out in the Department of Pharmacology at the Iran University of Medical Sciences during the years of 2009-2011. An experimental model of HF was induced in male Wistar rats using doxorubicin (DOX). The rats were divided into five groups with seven animals in each group: normal control group, DOX-induced HF control groups, and treatment groups. The animals were administered DOX for 15 days. A consistent deterioration occurred after a four-week rest period. The animals were then treated with intraperitoneal mebudipine (0.5 mg/kg) and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal volume of distilled water for 15 days. The plasma levels of big endothelin-1 (BET-1), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), as well as the clinical status (heart rate and blood pressure), were assessed before and after treatment. Statistical analysis was performed with SPSS software using parametric and nonparametric ANOVA. RESULTS: Mebudipine and amlodipine reversed the increased plasma BET-1 values in the treated animals when compared with the HF control group (0.103 and 0.112 vs 0.231 pg/mL, respectively). The increased plasma levels of AST, ALT, CK-MB, and LDH were also reversed in the HF animals that received mebudipine or amlodipine. CONCLUSION: The administration of mebudipine to HF animals, akin to amlodipine, palliated the clinical and biochemical signs of the disease in the present study. The abstract was presented in the Iranian Congress of Physiology and Pharmacology as a poster and published in the Scientific Information Database as a supplement (2015; Vol 22). Shiraz University of Medical Sciences 2021-03 /pmc/articles/PMC7966930/ /pubmed/33753958 http://dx.doi.org/10.30476/ijms.2019.82057.0 Text en Copyright: © Iranian Journal of Medical Sciences http://creativecommons.org/licenses/by-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Aali, Ehsan
Ghaznavi, Habib
Soltanpour, Mohammad Soleiman
Mahmoudian, Massoud
Shafiei, Massoumeh
Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title_full Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title_fullStr Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title_full_unstemmed Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title_short Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure
title_sort cardioprotective effects of mebudipine in a rat model of doxorubicin-induced heart failure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966930/
https://www.ncbi.nlm.nih.gov/pubmed/33753958
http://dx.doi.org/10.30476/ijms.2019.82057.0
work_keys_str_mv AT aaliehsan cardioprotectiveeffectsofmebudipineinaratmodelofdoxorubicininducedheartfailure
AT ghaznavihabib cardioprotectiveeffectsofmebudipineinaratmodelofdoxorubicininducedheartfailure
AT soltanpourmohammadsoleiman cardioprotectiveeffectsofmebudipineinaratmodelofdoxorubicininducedheartfailure
AT mahmoudianmassoud cardioprotectiveeffectsofmebudipineinaratmodelofdoxorubicininducedheartfailure
AT shafieimassoumeh cardioprotectiveeffectsofmebudipineinaratmodelofdoxorubicininducedheartfailure